DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 🎓 Expert Commentary / Peer Perspective
For more than two decades, findings from the Women’s Health Initiative and the HABITS trial have influenced prescribing patterns for menopausal hormone therapy (MHT). This review argues that subsequent analyses, formulation-specific findings, long-term follow-up, and evolving regulatory guidance support a more individualized approach to counseling women with menopause symptoms, including some breast cancer survivors.
Clinical Considerations
- Historical concerns about MHT largely stemmed from findings in the Women’s Health Initiative and HABITS trials.
- Subsequent analyses suggest risks may differ according to patient age, timing of initiation, hormone formulation, and tumor subtype.
- Estrogen-only and combined estrogen-progesterone regimens may carry different risk profiles.
- Published literature remains mixed, with some studies reporting increased recurrence risk and others finding no significant increase in recurrence or mortality.
- Younger breast cancer survivors may face substantial consequences from estrogen deficiency, including cardiovascular disease, osteoporosis, and reduced quality of life.
- Current evidence continues to support individualized risk-benefit assessment rather than a one-size-fits-all approach.
Practice Applications
- Recognize differences among hormone formulations when discussing menopausal therapy risks.
- Interpret historical MHT trial findings within the context of later analyses and follow-up data.
- Engage breast cancer survivors in shared decision-making regarding symptom management goals.
- Consider patient age, cancer subtype, treatment history, and symptom burden during counseling.
- Review nonhormonal and hormonal management options within an individualized care framework.
- Avoid assuming historical trial findings apply equally to all survivors and formulations.
